HISOAR(SZ:002099) Xin Lang Cai Jing·2026-02-13 02:03Group 1 - Haisun Pharmaceutical's stock price dropped by 5.07% to 7.87 CNY per share, with a trading volume of 178 million CNY and a turnover rate of 1.36%, resulting in a total market capitalization of 12.739 billion CNY [1] - The company, established on May 7, 1998, and listed on December 26, 2006, is located in Taizhou, Zhejiang Province, and specializes in the production and sales of fine chemicals (intermediates for active pharmaceutical ingredients) and specialty active pharmaceutical ingredients, including antibiotics, antiviral drugs, cardiovascular drugs, antiparasitics, and antidiabetic drugs [1] - The revenue composition of Haisun Pharmaceutical includes 56.07% from active pharmaceutical ingredients and intermediates, 33.09% from dyes and dye intermediates, 9.34% from contract customization services, 1.02% from other sources, and 0.49% from formulations [1] Group 2 - Among the top circulating shareholders of Haisun Pharmaceutical, a fund under Southern Fund holds a significant position, with the Southern CSI 1000 ETF (512100) reducing its holdings by 170,300 shares in the third quarter, now holding 10.3583 million shares, which accounts for 0.64% of the circulating shares [2] - The estimated floating loss for the Southern CSI 1000 ETF today is approximately 4.3505 million CNY [2] - The Southern CSI 1000 ETF was established on September 29, 2016, with a current scale of 78.996 billion CNY, yielding a return of 9.47% this year, ranking 1524 out of 5569 in its category, and a one-year return of 34.09%, ranking 1864 out of 4295 [2]